Search results for "MCI"

showing 10 items of 228 documents

New Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modu…

2020

Background/aim A new class of imidazo[2,1-b][1,3,4]thiadiazole compounds have recently been evaluated as inhibitors of phosphorylation of focal adhesion kinase (FAK) in pancreatic cancer. FAK is overexpressed in mesothelioma and has recently emerged as an interesting target for the treatment of this disease. Materials and methods Ten imidazo[2,1-b][1,3,4]thiadiazole compounds characterized by indole bicycle and a thiophene ring, were evaluated for their cytotoxic activity in two primary cell cultures of peritoneal mesothelioma, MesoII and STO cells. Results Compounds 1a and 1b showed promising antitumor activity with IC50 values in the range of 0.59 to 2.81 μM in both cell lines growing as …

MesotheliomaCancer ResearchFAKbiologyChemistrygemcitabineSettore BIO/05 - Zoologiaimidazo[21-b][134]thiadiazole compoundGeneral MedicineEquilibrative nucleoside transporter 1medicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGemcitabineFocal adhesionOncologyCell culturePancreatic cancerbiology.proteinmedicineCancer researchPhosphorylationCytotoxic T cellhuman equilibrative nucleoside transporter-1.Nucleosidemedicine.drugAnticancer Research
researchProduct

Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A co…

2020

Abstract Background Expression of proton-coupled folate transporter (PCFT) is associated with survival of mesothelioma patients treated with pemetrexed, and is reduced by hypoxia, prompting studies to elucidate their correlation. Methods Modulation of glycolytic gene expression was evaluated by PCR arrays in tumour cells and primary cultures growing under hypoxia, in spheroids and after PCFT silencing. Inhibitors of lactate dehydrogenase (LDH-A) were tested in vitro and in vivo. LDH-A expression was determined in tissue microarrays of radically resected malignant pleural mesothelioma (MPM, N = 33) and diffuse peritoneal mesothelioma (DMPM, N = 56) patients. Results Overexpression of hypoxia…

MesotheliomaCancer ResearchPleural NeoplasmsCell Culture TechniquesPemetrexedDeoxycytidineArticle03 medical and health sciencesMice0302 clinical medicinelactate dehydrogenase inhibitorsIn vivoAntigens NeoplasmCell Line TumormedicineGene silencingAnimalsHumansMesotheliomaEnzyme InhibitorsCarbonic Anhydrase IXPeritoneal Neoplasms030304 developmental biology0303 health sciencesL-Lactate DehydrogenaseCell growthChemistryhypoxiaMesothelioma MalignantDrug SynergismHypoxia (medical)Translational researchmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaXenograft Model Antitumor AssaysGemcitabineGemcitabineCell HypoxiaGene Expression Regulation NeoplasticPemetrexedOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisPeritoneal mesotheliomaCancer researchFemalemedicine.symptomProton-Coupled Folate Transportermedicine.drugBritish journal of cancer
researchProduct

Obese rats exhibit high levels of isoprostanes in acute pancreatitis

2012

s / Pancreatology 12 (2012) 502–597 538 interference of Sam68 and SRSF1 expression cause a partial recovery of drug sensitivity. Conclusions: Our results show that chronic exposure of PDAC cells to gemcitabine leads to selection of a drug-resistant subpopulation overexpressing Sam68 and SRSF1. Importantly, the depletion of these proteins leads to a partial recovery of the sensibility to gemcitabine, suggesting that they may represent suitable molecular-targets to overcome drug resistance in PDAC. Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009 Jul Shapiro IM, Cheng AW, Flytzanis NC, et…

Messenger RNAHepatologybusiness.industryEndocrinology Diabetes and MetabolismCellAlternative splicingGastroenterologyCancermedicine.diseaseGemcitabinemedicine.anatomical_structurePancreatic cancerRNA splicingmedicineCancer researchEpithelial–mesenchymal transitionbusinessmedicine.drugPancreatology
researchProduct

Microscopic Study of Injectable Steroids: Effects of Postmixing Time on Particle Aggregation

2020

Background: Epidural steroid injection (ESI) is a common practice for pain treatment since 1953. In 2014, the FDA issued a warning about ESI. Studies have focused on the effect of the particle size and their ability to generate harmful aggregates. Although steroid aggregates provide longer times for reabsorption, therefore a longer anti-inflammatory effect, they are potentially harmful to the central nervous system via embolic mechanisms. Previous studies have established that steroidal aggregates with asizes over 100 μm are potentially able to occlude blood vessels. Studies by Tiso et al and Benzon et al addressed the role of steroids on CNS adverse events, with similar outcomes. The main …

MicroscopyR softwareTriamcinolone acetonidebusiness.industryEpidural steroid injectionmedicine.medical_treatmentInjections EpiduralPharmacologyTriamcinoloneBetamethasoneDexamethasoneSteroidParticle aggregationAnesthesiology and Pain MedicineHumansMedicineBetamethasoneSteroidsParticle sizeParticle SizebusinessGlucocorticoidsDexamethasonemedicine.drugPain Physician
researchProduct

Hlorēto parafīnu un bromēto antipirēnu noteikšana apkārtējās vides paraugos no Svalbāras, izmantojot augstas izšķirtspējas masspektrometriju

2022

Maģistra darbā ir apkopota informācija bromēto antipirēnu un hlorēto parafīnu izmantošanas vēsturi, īpašībām un izplatības dinamiku līdz polāriem reģioniem, ar fokusu uz heksabromciklododkānu. Papildus, tika apkopota informācijā no literatūras par šo savienojumu sastopamību apkārtējās vides paraugos no Arktikas un Antarktīdas. Iepriekš izstrādāta paraugu sagatavošanas metode eksperimentālā daļā tika optimizēta, izvērtējot izvēlēto fāžu efektivitāti bromēto antipirēnu frakcionēšanai. Paraugu sagatavošanas procedūru pielietoja paraugos esošu piesārņotāju profilu raksturošanai un daudzumu noteikšanai Eiropas Arktikas izcelsmes augsnes paraugos.

Noturīgie organiskie piesārņotājiHeksabromciklododekāniPolibromētie difenilēteriĶīmijaHlorētie parafīniAugstas izšķirtspējas masspektrometrija
researchProduct

Electrospun Plasma-assisted Functionalized Ocular Inserts for Triamcinolone Acetonide Delivery

2018

Topically administered ocular Drug Delivery Systems are the most desirable formulations for the treatment of ocular chronic diseases, being the most simple, convenient and patient-friendly ocular route of administration, despite it requires prolonged and continuous treatment over time. At this regard, ocular insert represent an innovative and effective strategy. Ocular inserts are solid/semisolid sterile preparations characterized by dimensions and shape specifically designed for topical ocular administration. They are able to rapidly adhere on the ocular surface and remain in situ for prolonged period while assuring a controlled drug release and potentially increasing drug transcorneal abs…

Ocular insert Triamcinolone Acetonide Plasma-assisted functionalization.
researchProduct

CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective r…

2015

4007 Background: Adjuvant chemotherapy with gemcitabine (Gem) for 6 months significantly improves survival of pancreatic cancer patients. CONKO-005 was designed to evaluate an additional effect of ...

Oncology0303 health sciencesCancer Researchmedicine.medical_specialtyendocrine system diseasesAdjuvant chemotherapybusiness.industrymedicine.diseaseGemcitabine3. Good health03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisPancreatic cancerInternal medicinemedicineAdjuvant therapyErlotinibbusiness030304 developmental biologymedicine.drugJournal of Clinical Oncology
researchProduct

“Weekly docetaxel and gemcitabine as first line treatment for metastatic breast cancer: results of a multicenter phase II study”

2004

<i>Objectives:</i> We conducted a multicenter phase II study to evaluate the clinical efficacy, toxicity, and dose intensity of a new weekly schedule of docetaxel and gemcitabine as first-line treatment of metastatic breast cancer patients. <i>Methods:</i> We enrolled 58 patients, 52% of whom had received a previous anthracycline-containing chemotherapy. The treatment schedule was: docetaxel 35 mg/m<sup>2</sup> and gemcitabine 800 mg/m<sup>2</sup> i.v. on days 1, 8, 15 every 28 days. <i>Results:</i> All patients were assessable for toxicity and 56 for efficacy. Overall response rate was 64.3% with 16.1% of complete responses and 48…

OncologyAdultCancer Researchmedicine.medical_specialtyMaximum Tolerated Dosemedicine.drug_classPhases of clinical researchBreast NeoplasmsDocetaxelAntimetaboliteDeoxycytidineMetastasisBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedNeoplasm Stagingbusiness.industryCarcinoma Ductal BreastGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerGemcitabineGemcitabineSurgerySurvival RateCarcinoma LobularTreatment OutcomeOncologyDocetaxelCarcinoma MedullaryToxicityFemaleTaxoidsbusinessmedicine.drug
researchProduct

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy

2010

Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients eligible for second-line treatment is scarce. The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival.Methods: individual data from nine randomised trials of second-line treatment in advanced NSCLC were analysed. Primary end-point was overall survival (OS). Cox model, stratified by trial, was used for multivariate analyses, and a prognostic index was provided and validated according to an internal/external procedure.Results: Out of 1239 patients, 119…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisLung NeoplasmsWEEKLY DOCETAXELIRINOTECANCOMBINATION CHEMOTHERAPYAntineoplastic AgentsERLOTINIBPrognostic factorsNSCLCTHERAPYPooled analysisPLUS GEMCITABINEInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Lung cancerEVERY 3 WEEKSAgedNeoplasm StagingRandomized Controlled Trials as TopicAged 80 and overPerformance statusProportional hazards modelbusiness.industryAge FactorsCombination chemotherapyPHASE-III TRIALMiddle Agedmedicine.diseasePrognosisTreatment OutcomeOncologyMeta-analysisPrognostic scoreCOMPARING DOCETAXELSecond-line treatmentAdenocarcinomaFemalebusinessEpidemiologic MethodsNon-small-cell lung cancerEuropean Journal of Cancer
researchProduct

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised pros…

2008

Platinum/taxane combinations are widely used in patients with carcinoma of unknown primary (CUP), yielding response rates of 30% and median overall survival of 9-11 months in selected patients. Yet these combinations have not been subject to a randomised trial to overcome selection bias, a major problem in CUP. We randomised 92 patients to either paclitaxel/carboplatin (arm A) or the non-platinum non-taxane regimen gemcitabine/vinorelbine (arm B). The primary endpoint was rate of practicability as defined: application of >or=2 cycles of therapy (1) with a maximal delay of 1 week (2) and survival of >or=8 months (3). Practicability was shown in 52.4% (95% CI 36-68%) in arm A and in 42.2% (95…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentneoplasmsVinorelbineVinblastineDeoxycytidineCarboplatinchemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineClinical endpointHumansProspective StudiesAgedProportional Hazards ModelsChemotherapyTaxaneclinical trial phase IIbusiness.industryVinorelbineMiddle AgedGemcitabinemedical oncologyGemcitabineCarboplatinSurgeryErbB ReceptorsRegimenOncologyDocetaxelchemistryrandomized controlled trialunknown primaryNeoplasms Unknown Primaryanti-neoplastic-combined chemotherapy protocolsFemalebusinessmedicine.drugBritish journal of cancer
researchProduct